Natera, Inc. (NASDAQ:NTRA) is one of the 8 Best Genomics Stocks to Buy According to ******* ysts.
On June 5, Goldman Sachs initiated coverage on Natera, Inc. (NASDAQ:NTRA) with a Neutral rating and a $245 price target, noting the firm's leadership in the molecular residual disease testing market. ******* yst Evie Koslosky pointed to "strong" commercial execution and a tumor-informed approach resulting in higher sensitivity. Goldman is expecting clearer operating leverage as the company continues reinvesting in growth.
On June 4, Natera, Inc. (NASDAQ:NTRA) announced a collaboration with CytoDyn to evaluate circulating tumor DNA dynamics in metastatic colorectal cancer. Under the agreement, Natera said it will examine CLOVER Phase 2 trial samples using its Signatera ******* ay. It will also deliver real-world data insights drawn from a database exceeding 2 million plasma timepoints.
Likoper/Shutterstock.com
CytoDyn CEO Jacob Lalezari said the partnership will generate insights into "ctDNA response kinetics and disease progression." Natera's Vice President, Biopharma Data & AI Partnering, Matt Love, added that the platform helps partners "better understand disease biology, treatment response, and patient outcomes."
On June 5, Goldman Sachs initiated coverage on Natera, Inc. (NASDAQ:NTRA) with a Neutral rating and a $245 price target, noting the firm's leadership in the molecular residual disease testing market. ******* yst Evie Koslosky pointed to "strong" commercial execution and a tumor-informed approach resulting in higher sensitivity. Goldman is expecting clearer operating leverage as the company continues reinvesting in growth.
On June 4, Natera, Inc. (NASDAQ:NTRA) announced a collaboration with CytoDyn to evaluate circulating tumor DNA dynamics in metastatic colorectal cancer. Under the agreement, Natera said it will examine CLOVER Phase 2 trial samples using its Signatera ******* ay. It will also deliver real-world data insights drawn from a database exceeding 2 million plasma timepoints.
Likoper/Shutterstock.com
CytoDyn CEO Jacob Lalezari said the partnership will generate insights into "ctDNA response kinetics and disease progression." Natera's Vice President, Biopharma Data & AI Partnering, Matt Love, added that the platform helps partners "better understand disease biology, treatment response, and patient outcomes."
2 months ago
